Evolving Targets for Risk Reduction in Diabetes

Gregory M. Caputo, Joel B. Braunstein, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

Recent evidence shows that target low-density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.

Original languageEnglish (US)
Pages (from-to)125-128
Number of pages4
JournalClinical Cardiology
Volume27
Issue number3
StatePublished - Mar 2004

Fingerprint

Risk Reduction Behavior
LDL Cholesterol
Blood Glucose
Blood Pressure
Delivery of Health Care
Therapeutics

Keywords

  • Blood pressure
  • Cholesterol
  • Diabetes mellitus
  • Glucose
  • Hyperlipidemia
  • Hypertension
  • Lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Caputo, G. M., Braunstein, J. B., & Blumenthal, R. S. (2004). Evolving Targets for Risk Reduction in Diabetes. Clinical Cardiology, 27(3), 125-128.

Evolving Targets for Risk Reduction in Diabetes. / Caputo, Gregory M.; Braunstein, Joel B.; Blumenthal, Roger S.

In: Clinical Cardiology, Vol. 27, No. 3, 03.2004, p. 125-128.

Research output: Contribution to journalArticle

Caputo, GM, Braunstein, JB & Blumenthal, RS 2004, 'Evolving Targets for Risk Reduction in Diabetes', Clinical Cardiology, vol. 27, no. 3, pp. 125-128.
Caputo, Gregory M. ; Braunstein, Joel B. ; Blumenthal, Roger S. / Evolving Targets for Risk Reduction in Diabetes. In: Clinical Cardiology. 2004 ; Vol. 27, No. 3. pp. 125-128.
@article{ba8b0a1e0473426fa93ee2472924a1e7,
title = "Evolving Targets for Risk Reduction in Diabetes",
abstract = "Recent evidence shows that target low-density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.",
keywords = "Blood pressure, Cholesterol, Diabetes mellitus, Glucose, Hyperlipidemia, Hypertension, Lipids",
author = "Caputo, {Gregory M.} and Braunstein, {Joel B.} and Blumenthal, {Roger S}",
year = "2004",
month = "3",
language = "English (US)",
volume = "27",
pages = "125--128",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Evolving Targets for Risk Reduction in Diabetes

AU - Caputo, Gregory M.

AU - Braunstein, Joel B.

AU - Blumenthal, Roger S

PY - 2004/3

Y1 - 2004/3

N2 - Recent evidence shows that target low-density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.

AB - Recent evidence shows that target low-density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.

KW - Blood pressure

KW - Cholesterol

KW - Diabetes mellitus

KW - Glucose

KW - Hyperlipidemia

KW - Hypertension

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=1442353588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442353588&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 125

EP - 128

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 3

ER -